✦ LIBER ✦

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

✍ Scribed by T. Ramón y Cajal; A. Altés; L. Paré; E. del Rio; C. Alonso; A. Barnadas; M. Baiget

Publisher: Springer US
Year: 2009
Tongue: English
Weight: 177 KB
Volume: 119
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-009-0328-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The CYP2D6*4 polymorphism affects breast

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

✍ Monique J. Bijl; Ron H. N. van Schaik; Laureen A. Lammers; Albert Hofman; Arnold 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 207 KB

CYP2D6 polymorphisms and the impact on t

CYP2D6 polymorphisms and the impact on tamoxifen therapy

✍ Jacob N. Beverage; Tristan M. Sissung; Amy M. Sion; Romano Danesi; William D. Fi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

The cytochrome P450 2D6 (CYP2D6) is an enzyme known to metabolize a variety of xenobiotics and drugs. Inter-individual variation in the metabolic capacity of this enzyme has been extensively studied and associations with genotype have been established. Genetic polymorphisms have been grouped as nonf

Effect of CYP2D6 polymorphisms on breast

Effect of CYP2D6 polymorphisms on breast cancer recurrence

✍ Phuong K. Morrow; Ruben Serna; Kristine Broglio; Lajos Pusztai; D. Michelle Niko 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 768 KB

Lack of any association between function

Lack of any association between functionally significantCYP2D6polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment

✍ In Hae Park; Jungsil Ro; Sohee Park; Hyeong-Seok Lim; Keun Seok Lee; Han Sung Ka 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 333 KB

Potent CYP2D6 Inhibiting drugs do not in

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

✍ Nava Siegelmann-Danieli; Daniel Kurnik; Yossi Lomnicky; Janet Vesterman-Landes; 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 170 KB

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions